Newark, CA – According to filings with the U.S. Securities and Exchange Commission, InCarda Therapeutics is raising $50,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Grace Colon played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About InCarda Therapeutics

InCarda Therapeutics, Inc. is a privately-held, clinical-stage biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions by the inhalation route. The advantage of inhalation is that it delivers medicine in the first pass to cardiac tissue, presenting a small, but effective dose of drug directly to affected regions of the heart. This permits rapid-onset, lower off-target tissue exposure of the drug, lower continued/prolonged exposure to cardiac tissue and, more importantly, can be patient self-administered anywhere PAF episodes may occur. The lead product under development is an inhaled therapy to treat paroxysmal atrial fibrillation (PAF), a widespread atrial arrhythmia. InCarda employs a de-risked approach by using approved drugs with a long history of efficacy and safety in a new dosing paradigm.

To learn more about InCarda Therapeutics, visit http://incardatherapeutics.com/

Contact:
Grace Colon, President and Chief Executive Officer
408-219-2576
https://www.linkedin.com/in/gracecolon/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved